India · Delayed Price · Currency is INR Dr. Reddy's Laboratories Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY 2026 delivered 4.4% revenue growth and strong base business performance, offset by lower lenalidomide sales and pricing pressure in US and Europe generics. India and emerging markets saw robust double-digit growth, while biosimilar launches and regulatory progress continue to drive future outlook.
-
Q2 FY26 saw 9.8% revenue growth and 14% profit rise year-over-year, led by consumer healthcare and ex-US markets, despite US generics pressure. Strategic launches, biosimilar progress, and disciplined cost control support a positive outlook, with margin recovery expected in two years.
-
Q1 FY26 delivered 11% revenue growth and a 26.7% EBITDA margin, with strong performance in India, Europe, and emerging markets offsetting U.S. generic price erosion. Strategic investments in biosimilars and consumer health, plus a robust pipeline, position the company for sustainable growth.
Fiscal Year 2025
-
Record annual revenue and EBITDA were achieved, driven by acquisitions and strong generics growth. Double-digit growth is expected to continue in FY 2026, with robust R&D investment and margin maintenance, despite upcoming patent expiries and evolving market risks.
-
Double-digit revenue and EBITDA growth were driven by the NRT acquisition and strong performance across key markets. R&D and SG&A investments remain elevated, with a focus on biosimilars, semaglutide, and innovation. Integration of the NRT business and new product launches are expected to support future growth.
-
Q2 FY25 saw record sales and operating profits, with 17% YoY revenue growth and robust margins. Key acquisitions, strong launches, and expansion in biosimilars and peptides support future growth, while regulatory and one-time items impacted results.
-
Q1 FY25 saw 14% revenue growth, record-high revenues, and stable margins, driven by strong North America and India performance, new launches, and strategic acquisitions. SG&A rose due to investments and one-off freight costs, while the company maintains a robust cash position and double-digit growth outlook.
Fiscal Year 2024
-
A definitive agreement was signed to acquire a global NRT portfolio, including Nicotinell, for GBP 500 million, expanding the OTC platform in 30+ markets. The deal is margin-accretive, leverages established CMOs, and is expected to close in early Q4 2024, supporting long-term growth ambitions.